Daina Graybosch, Ph.D., is a Senior Research Analyst at Leerink Partners covering Immuno-Oncology. Prior to joining the Firm in 2018, Daina worked at McKinsey & Company as a Senior Expert and Head of McKinsey’s Center for Asset Optimization, as well as the U.S. Head of the McKinsey Cancer Center.

Jun 18, 2018 · Dr. Graybosch joins Leerink Partners from McKinsey & Company where she was most recently a Senior Expert and Head of McKinsey’s Center for Asset Optimization, as well as the U.S. Head of the McKinsey Cancer Center.

Daina Graybosch is a Wall Street analyst working for Leerink Partners. Daina has covered 17 stocks with a 34.09% success rate and an average return of -14%.

Daina Graybosch has extensive work experience in the field of biotechnology analysis and consulting. Daina is currently serving as the Senior Managing Director and Biotechnology Analyst, specializing in Immuno-Oncology, at Leerink Partners since February 2022.

Daina Graybosch, Ph.D., is a Senior Research Analyst at Leerink Partners covering Immuno-Oncology. Prior to joining the Firm in 2018, Daina worked at McKinsey & Company as a Senior Expert and Head of McKinsey’s Center for Asset Optimization, as well as the U.S. Head of the McKinsey Cancer Center.

BrokerCheck offers information on all current, and many former, registered securities brokers, and all current and former registered securities firms. FINRA strongly encourages investors to use BrokerCheck to check the background of securities brokers and brokerage firms before deciding to conduct, or continue to conduct, business with them.

Daina Graybosch Biography. Daina Graybosch Biography . Daina Graybosch SVB Leerink. [email protected]. BioNTech SE. An der Goldgrube 12. 55131 Mainz, Germany. T: +49 6131 9084-0. F: +49 6131 9084-2121. [email protected]. Company. About Research & Innovation Pipeline ...

Sep 14, 2020 · Daina Graybosch is a Senior Research Analyst at SVB Leerink covering Immuno-Oncology. Prior to joining the firm in 2018, Dr Graybosch worked at McKinsey & Company as a Senior Expert and Head of Mckinsey’s Center for Asset Optimization, as well as the US Head of the McKinsey Cancer Center.

Mar 29, 2024 · Analyst Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report) and keeping the price target at $129.00. Daina Graybosch has given her Buy...